This is the first time to our knowledge that a CDH6-targeted ADC has demonstrated antitumor efficacy in settings other than ovarian cancer and RCC and indicate CUSP06 could have therapeutic potential in CDH6-positive uterine cancer and cholangiocarcinoma patients. Here, CDH6 is linked to ovarian cancer.